Mefenamic Acid: meta-analysis of COVID-19 studies

All studies   Hospitalization   Serious outcomes   RCTs   Peer-reviewed   All outcomes  
Meta-analysis1 study · 36 patientsc19early.org

Mefenamic Acid for COVID-19

Serious outcome risk
Mefenamic Acid
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−189%
Hospitalization (1)−189%
RCTs (1)−189%
Early (1)−189%
00.511.5+
← Mefenamic Acid
reduces riskIncreased
risk →
c19early.org
October 2026

Mefenamic acid COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Guzman‑.. (DB RCT)−189%2.89 · 0.13–66.66hosp.1/190/17MEFECOVID-19
Early treatment−189%2.89 · 0.13–66.661/190/17189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−189%2.89 · 0.13–66.661/190/17189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← Mefenamic Acid
reduces riskMefenamic Acid
increases risk →
c19early.org
October 2026

Mefenamic acid COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Guzman‑.. (DB RCT)−189%2.89 · 0.13–66.66hosp.1/190/17MEFECOVID-19
Early treatment−189%2.89 · 0.13–66.661/190/17189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−189%2.89 · 0.13–66.661/190/17189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← Mefenamic Acid
reduces riskMefenamic Acid
increases risk →
c19early.org
October 2026

Mefenamic acid COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Guzman‑.. (DB RCT)−189%2.89 · 0.13–66.66hosp.1/190/17MEFECOVID-19
Early treatment−189%2.89 · 0.13–66.661/190/17189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−189%2.89 · 0.13–66.661/190/17189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← Mefenamic Acid
reduces riskMefenamic Acid
increases risk →
c19early.org
October 2026

Mefenamic acid COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Guzman‑.. (DB RCT)−189%2.89 · 0.13–66.66hosp.1/190/17MEFECOVID-19
Early treatment−189%2.89 · 0.13–66.661/190/17189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−189%2.89 · 0.13–66.661/190/17189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← Mefenamic Acid
reduces riskMefenamic Acid
increases risk →
c19early.org
October 2026

Mefenamic acid COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Guzman‑.. (DB RCT)−189%2.89 · 0.13–66.66hosp.1/190/17MEFECOVID-19
Early treatment−189%2.89 · 0.13–66.661/190/17189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−189%2.89 · 0.13–66.661/190/17189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← Mefenamic Acid
reduces riskMefenamic Acid
increases risk →